海创药业：12月8日召开董事会会议

Group 1 - The core viewpoint of the article highlights that Haichuang Pharmaceutical (SH 688302) held its 15th meeting of the second board on December 8, 2025, to discuss amendments to the company's articles of association [1] - For the first half of 2025, Haichuang Pharmaceutical's revenue composition was 99.25% from pharmaceuticals and 0.75% from materials and R&D intermediates [1] - As of the report, Haichuang Pharmaceutical has a market capitalization of 4.7 billion yuan [1] Group 2 - The article also discusses the emergence of addiction cases related to the misuse of pregabalin in China, marking the first report of such incidents [1] - It mentions that online platforms have exposed vulnerabilities in purchasing medications without medical records, raising concerns about regulatory oversight [1] - The classification of pregabalin and the need for scientific evaluation regarding its regulation are emphasized [1]